

ANNOUNCEMENT OF NOMINATIONS OF MR. D.E. LAZAR FOR APPOINTMENT AS EXECUTIVE DIRECTOR AND OF MR. R. LISCOUSKI, MR. D. NATAN, AND MR. A.S. BEN-TZVI FOR APPOINTMENT AS NON-EXECUTIVE DIRECTOR

23 March March 2026. Mainz Biomed N.V. announces that Mr. D.E. Lazar has been nominated by the board for appointed as executive director and that Mr. R. Liscouski, Mr. D. Natan, and Mr. A.S. Ben-Tzvi have been nominated by the board for appointed as non-executive director of Mainz Biomed N.V. at the extraordinary general meeting of Mainz Biomed N.V. to be held on Wednesday 22 April 2026.

1. Mr. D.E. Lazar

It is proposed that Mr. David E. Lazar be appointed executive director of the Company for a term commencing at the close of the EGM and ending at the close of the annual general meeting of the Company to be held in 2027.

Mr. Lazar currently serves as the CEO and Chairman of Mainz Biomed N.V. (MYNZ) since February, and Sow Good, Inc. (NASDAQ: SOWG) since January 2026. Previously, David served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026. David previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August to November 2025. Prior to that, David served as a director on the Board of Directors of FiEE, Inc. (NASDAQ: FIEE) (formerly Minim, Inc.) where he also served as CEO and CFO from December 2023 to February 2025. David served as interim CEO and principal Financial Officer of Bio Green Med Solution Inc. (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.) from 2 January 2025 through 26 February 2025. David served as the CEO of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.) from August 2022 to April 2024, where he also served as a Director and board Chairman from August 2022 until October 2023. David also served as the CEO and Chairman of the Board of Directors of OpGen, Inc. (OTC: OPGN) from March 2024 to August 2024. David also served as the President and a member of the Board of Directors of LQR House Inc. (NASDAQ: YHC) from October 2024 to April 2025. David served as the CEO of Activist Investing from March 2018 to April 2022. The Board believes that David's expertise as an investor with diverse knowledge of capital markets and experience leading public companies qualifies him to serve as a member of the Company's Board of Directors.

When making the nomination of Mr. Lazar for appointment as executive director, the board of directors took into account the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC.

Mr. Lazar currently holds 1,000,000 series A preferred shares, 1,000,000 series B preferred shares, and 1,000,000 series C preferred shares in the capital of the Company.

2. Mr. R. Liscouski

It is proposed that Mr. Robert Liscouski be appointed non-executive director of the Company for a term commencing at the close of the EGM and ending at the close of the annual general meeting of the Company to be held in 2027.

Mr. Liscouski is Chairman of the Board of Quantum Computing, Inc. He has served in this position since February 2018. From March 2018 through January 2024, Mr. Liscouski served as Chief Executive Officer and President of Quantum Computing, Inc. Prior to that, Mr. Liscouski served as Chairman and Founder of Convergent Risk Group LLC, an enterprise security risk management firm specialising in the convergence of physical and cyber risk, from January 2011 through May 2019 and as President of Implant Sciences Corp., a public company that became a leader in the explosive trace detection industry culminating in the sale of the technology to L3 Communications in January 2017. Mr. Liscouski is a proven security professional, thought leader and successful entrepreneur with over 35 years of senior level security operational and company leadership experience in government and public and private companies.

Mr. Liscouski is a recognised security industry leader in assessing, mitigating and managing physical and cybersecurity risk in private sector enterprises and state and federal government agencies. Mr. Liscouski has extensive experience in leading innovative start up and turnaround companies as well as building programs for large government organisations and is recognised as a leader in identifying emerging security technologies. He serves as a "Trusted Advisor" to senior officials within government and private sector, providing guidance in areas such as physical and cyber security, crisis management, organisational development and strategic planning. Mr. Liscouski's career has spanned local law enforcement, senior government and private sector positions from operations to senior leadership and boards of directors. He served as a senior advisor to the intelligence community and was appointed by President George W. Bush as the first Assistant Secretary for Infrastructure Protection at the Department of Homeland Security. Mr. Liscouski is a Founder and Chairman of the Board of the National Child Protection Task Force, a 501(c)(3) charitable organisation, and served on the Board of Clean Coal Technologies Inc. from 2019 until December 2020. He received his Bachelor of Science degree in Criminal Justice from John Jay College and his MPA in Public Administration from the Kennedy School of Government, Harvard University.

When making the nomination of Mr. Liscouski for appointment as non-executive director, the board of directors took into account the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC.

3. Mr. D. Natan

It is proposed that Mr. David Natan be appointed non-executive director of the Company for a term commencing at the close of the EGM and ending at the close of the annual general meeting of the Company to be held in 2027.

Mr. Natan, currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007. From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of Forcefield Energy, Inc., a company focused on the solar industry and LED lighting products. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of PharmaNet Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and

speakers and speaker components. Before that, Mr. Natan served various roles in increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (NASDAQ: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally, since April 2024, Mr. Natan has served as a member of the Board of Directors and Audit Committee Chair of FIEE, Inc. (formerly Minim, Inc.), a technology company specialising in SAAS solutions and AI software development. Previously, Mr. Natan has served as a director for the following public companies: Global Technovations, ForceField Energy, Black Titan (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.), Vivakor Inc. (NASDAQ: VIVK), NetBrands Corp. (OTC: NBND), OpGen Inc. (OTC: OPGN), and Bio Green Med Solutions (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.). Mr. Natan is a CPA (inactive), holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon, an international honour society in the field of Economics. The Board believes that Mr. Natan's financial expertise and experience with public companies and public company boards qualifies him to serve as a member of the Company's Board of Directors.

When making the nomination of Mr. Natan for appointment as non-executive director, the board of directors took into account the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC.

4. Mr. A.S. Ben-Tzvi

It is proposed that Mr. Avraham S. Ben-Tzvi be appointed non-executive director of the Company for a term commencing at the close of the EGM and ending at the close of the annual general meeting of the Company to be held in 2027.

Mr. Ben-Tzvi is the founder of ABZ Law Office, a boutique Israeli law firm specialising in corporate & securities laws, commercial law & contracts, and various civil law matters, as well as providing outsourced general counsel services for publicly traded as well as private companies and corporations, which he established in January 2017. Mr. Ben-Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumour immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben-Tzvi served as General Counsel and Company Secretary at Medigus Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturised imaging equipment company, from April 2014 until November 2015. Prior to that he served as an attorney at one of Israel's leading international law firms where, among other corporate and commercial work, he advised companies and underwriters on various offerings by Israeli companies listing in the US and on various SEC related filings. Prior to becoming a lawyer, Mr. Ben-Tzvi worked in several business development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development industries. Mr. Ben-Tzvi has been serving as a member of the Board of Directors of Black Titan Corporation (NASDAQ: BTTC), a distributor of human capital management software solutions in Southeast Asia, since 1 October 2025, following the completion of a merger with Titan Pharmaceuticals Inc. where he served as a director between August 2022 and the completion of the merger with Black Titan Corporation on 1 October

2025. Mr. Ben-Tzvi is a member of the Board of Directors of Indaptus Therapeutics, Inc. (NASDAQ: INDP) since 22 December 2025. Between 5 January 2025 and 2 April 2025, Mr. Ben-Tzvi served as a member of the Board of Directors of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) a pharmaceuticals development company. Between 15 October 2024 and 19 December 2024, Mr. Ben-Tzvi served as a member of the Board of Directors of LQR House, Inc. (NASDAQ: YHC), a company in the wine and spirits e commerce sector. Between 25 March 2024 and 2 August 2024, Mr. Ben-Tzvi served as a member of the Board of Directors of OpGen, Inc. (NASDAQ: OPGN), a precision medicine company. Between December 2023 and February 2025, Mr. Ben-Tzvi served as a member of the Board of Directors of Minim, Inc. (NASDAQ: MINM), a company which delivered smart software-driven communications products under the globally recognised Motorola brand and Minim® trademark. Mr. Ben-Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an L.L.B., magna cum laude from Sha'arei Mishpat College of Law in Hod HaSharon, Israel. Mr. Ben-Tzvi is a licensed attorney and member of the Israel Bar Association and is also licensed as a Notary by the Israeli Ministry of Justice. We believe that Mr. Ben-Tzvi's professional experience in banking and finance, as a corporate and securities lawyer, and his experience of working with domestic and foreign public companies listed in America qualifies him to serve as a member of the Company's Board of Directors.

When making the nomination of Mr. Ben-Tzvi for appointment as non-executive director, the board of directors took into account the applicable independence standards of the Stock Market Rules of the Nasdaq Stock Market LLC.